Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery.

Benhabbour SR, Kovarova M, Jones C, Copeland DJ, Shrivastava R, Swanson MD, Sykes C, Ho PT, Cottrell ML, Sridharan A, Fix SM, Thayer O, Long JM, Hazuda DJ, Dayton PA, Mumper RJ, Kashuba ADM, Victor Garcia J.

Nat Commun. 2019 Sep 20;10(1):4324. doi: 10.1038/s41467-019-12141-5.

2.

Brief Report: HIV Shedding in the Female Genital Tract of Women on ART and Progestin Contraception: Extended Follow-up Results of a Randomized Clinical Trial.

Kourtis AP, Wiener J, Hurst S, Nelson JAE, Cottrell ML, Corbett A, Chinula L, Msika A, Haddad LB, Tang JH.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):163-165. doi: 10.1097/QAI.0000000000002011.

PMID:
31095006
3.

Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.

Cottrell ML, Prince HMA, Schauer AP, Sykes C, Maffuid K, Poliseno A, Chun TW, Huiting E, Stanczyk FZ, Peery AF, Dellon ES, Adams JL, Gay C, Kashuba ADM.

Clin Infect Dis. 2019 Nov 27;69(12):2201-2204. doi: 10.1093/cid/ciz290.

PMID:
30963179
4.

Contemporary Drug-Drug Interactions in HIV Treatment.

Devanathan AS, Anderson DJC, Cottrell ML, Burgunder EM, Saunders AC, Kashuba ADM.

Clin Pharmacol Ther. 2019 Jun;105(6):1362-1377. doi: 10.1002/cpt.1393. Epub 2019 Mar 25.

PMID:
30739315
5.

Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.

Medina-Moreno S, Zapata JC, Cottrell ML, Le NM, Tao S, Bryant J, Sausville E, Schinazi RF, Kashuba AD, Redfield RR, Heredia A.

Antivir Ther. 2019;24(3):177-186. doi: 10.3851/IMP3285.

6.

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).

Imaz A, Niubó J, Cottrell ML, Perez E, Kashuba ADM, Tiraboschi JM, Morenilla S, Garcia B, Podzamczer D.

Clin Infect Dis. 2019 Sep 27;69(8):1403-1409. doi: 10.1093/cid/ciy1074.

PMID:
30561517
7.

The potential pitfalls of PrEP.

Cottrell ML, Dumond JB.

Lancet HIV. 2018 Nov 29. pii: S2352-3018(18)30318-7. doi: 10.1016/S2352-3018(18)30318-7. [Epub ahead of print] No abstract available.

PMID:
30503323
8.

Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.

Krovi SA, Gallovic MD, Keller AM, Bhat M, Tiet P, Chen N, Collier MA, Gurysh EG, Pino EN, Johnson MM, Shamim Hasan Zahid M, Cottrell ML, Pirone JR, Kashuba AD, Kwiek JJ, Bachelder EM, Ainslie KM.

Int J Pharm. 2018 Dec 1;552(1-2):371-377. doi: 10.1016/j.ijpharm.2018.10.017. Epub 2018 Oct 8.

9.

Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair.

Sykes C, Blake K, White N, Schauer AP, Guzman BB, Cottrell ML, Tamraz B, Kashuba ADM.

Anal Bioanal Chem. 2018 Nov;410(29):7773-7781. doi: 10.1007/s00216-018-1394-y. Epub 2018 Oct 2.

10.

A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.

Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, Dumond JB.

J Pharmacol Exp Ther. 2018 Nov;367(2):245-251. doi: 10.1124/jpet.118.251009. Epub 2018 Aug 27.

11.

Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques.

Brocca-Cofano E, Xu C, Wetzel KS, Cottrell ML, Policicchio BB, Raehtz KD, Ma D, Dunsmore T, Haret-Richter GS, Musaitif K, Keele BF, Kashuba AD, Collman RG, Pandrea I, Apetrei C.

J Virol. 2018 Aug 16;92(17). pii: e00576-18. doi: 10.1128/JVI.00576-18. Print 2018 Sep 1.

12.

Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.

Nicol MR, Corbino JA, Cottrell ML.

J Clin Pharmacol. 2018 Nov;58(11):1381-1395. doi: 10.1002/jcph.1270. Epub 2018 Jun 14. Review.

13.

Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.

Schauer AP, Sykes C, Cottrell ML, Prince H, Kashuba ADM.

J Pharm Biomed Anal. 2018 Feb 5;149:40-45. doi: 10.1016/j.jpba.2017.10.030. Epub 2017 Oct 31.

14.

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.

Cottrell ML, Garrett KL, Prince HMA, Sykes C, Schauer A, Emerson CW, Peery A, Rooney JF, McCallister S, Gay C, Kashuba ADM.

J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. doi: 10.1093/jac/dkx064.

15.

Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.

Maas BM, Francis O, Mollan KR, Lee C, Cottrell ML, Prince HM, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, Dumond JB.

PLoS One. 2016 Dec 30;11(12):e0168709. doi: 10.1371/journal.pone.0168709. eCollection 2016.

16.

p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

Dumond JB, Collins JW, Cottrell ML, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):120-127. doi: 10.1002/psp4.12150. Epub 2016 Dec 26.

17.

Interleukin (IL)-6 modulates transforming growth factor-β receptor I and II (TGF-βRI and II) function in epidermal keratinocytes.

Luckett-Chastain LR, Cottrell ML, Kawar BM, Ihnat MA, Gallucci RM.

Exp Dermatol. 2017 Aug;26(8):697-704. doi: 10.1111/exd.13260. Epub 2017 Mar 8.

18.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.

19.

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD.

J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.

20.

Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.

Cottrell ML, Patterson KB, Prince HM, Jones A, White N, Wang R, Kashuba AD.

Antivir Ther. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3.

21.

Pharmacokinetics of antiretrovirals in mucosal tissue.

Cottrell ML, Srinivas N, Kashuba AD.

Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):893-905. doi: 10.1517/17425255.2015.1027682. Epub 2015 Mar 22. Review.

22.

Topical microbicides and HIV prevention in the female genital tract.

Cottrell ML, Kashuba AD.

J Clin Pharmacol. 2014 Jun;54(6):603-15. doi: 10.1002/jcph.292. Epub 2014 Mar 28. Review.

23.

Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Cottrell ML, Hadzic T, Kashuba AD.

Clin Pharmacokinet. 2013 Nov;52(11):981-94. doi: 10.1007/s40262-013-0093-2. Review.

Supplemental Content

Loading ...
Support Center